Takeda’s anti-CCR8 ADC shows potent antitumor activity

May 8, 2026

Researchers from Takeda Pharmaceutical Co. Ltd. detailed the preclinical characterization of TAK-188, a first-in-class anti-CCR8 antibody-drug conjugate (ADC) designed to selectively target CCR8+ Tregs, alleviating immunosuppression in the tumor microenvironment.

BioWorld Science Conferences American Association for Cancer Research Cancer Antibody-drug conjugate Immuno-oncology

Today's news in brief

BioWorld

BioWorld briefs for May 8, 2026.

Rendering of a key measles protein targeted by neutralizing human antibodies

First measles treatment advances as vaccination rates drop

BioWorld

Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...

Infensa Bioscience identifies new ASIC blockers

BioWorld Science

Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.

Hantavirus is ‘sentinel’ more than acute pandemic threat

BioWorld

News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...

Art concept for inflammation in the intestines

Kymera’s IRF5 degrader shows potential in IBD treatment

BioWorld Science

At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...